About My Treatment (NI)
Close Mobile Navigation


  1. KEYTRUDA Patient Information Leaflet.
  2. Understanding MSI-H/dMMR FA.
  3. KEYTRUDA Summary of Product Characteristics.
  4. AVASTIN® (Bevacizumab) Patient Information Leaflet.
  5. INLYTA® (axitinib) Patient Information Leaflet.
  6. KISPLYX® (lenvatinib) Patient Information Leaflet.
  7. LENVIMA® (lenvatinib) Patient Information Leaflet.

Supporting documentation

KEYTRUDA® (pembrolizumab)

Summary of Product Characteristics | Patient Information Leaflet

GB-PDO-03168 | Date of Preparation: June 2024

Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom.
Registered in England No. 233687 © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.